174 related articles for article (PubMed ID: 18287262)
1. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates.
Jia F; Figueroa SD; Gallazzi F; Balaji BS; Hannink M; Lever SZ; Hoffman TJ; Lewis MR
J Nucl Med; 2008 Mar; 49(3):430-8. PubMed ID: 18287262
[TBL] [Abstract][Full Text] [Related]
2. Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.
Jia F; Balaji BS; Gallazzi F; Lewis MR
Nucl Med Biol; 2015 Nov; 42(11):809-15. PubMed ID: 26239085
[TBL] [Abstract][Full Text] [Related]
3. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
[TBL] [Abstract][Full Text] [Related]
4. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene.
Gallazzi F; Wang Y; Jia F; Shenoy N; Landon LA; Hannink M; Lever SZ; Lewis MR
Bioconjug Chem; 2003; 14(6):1083-95. PubMed ID: 14624621
[TBL] [Abstract][Full Text] [Related]
6. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding.
Lewis MR; Jia F; Gallazzi F; Wang Y; Zhang J; Shenoy N; Lever SZ; Hannink M
Bioconjug Chem; 2002; 13(6):1176-80. PubMed ID: 12440850
[TBL] [Abstract][Full Text] [Related]
7. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.
Suzuki T; Wu D; Schlachetzki F; Li JY; Boado RJ; Pardridge WM
J Nucl Med; 2004 Oct; 45(10):1766-75. PubMed ID: 15471847
[TBL] [Abstract][Full Text] [Related]
8. Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors.
Zhao X; Wang N; Ren X; Zhang J; Wang J; Han J; Jia L; Liu Y; Zhang Z
J Nucl Med; 2014 Jun; 55(6):1008-16. PubMed ID: 24744447
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity of targeted proapoptotic peptides.
Capello A; Krenning EP; Bernard BF; Breeman WA; Erion JL; de Jong M
J Nucl Med; 2006 Jan; 47(1):122-9. PubMed ID: 16391196
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of targeted antisense 177Lu radiotherapy.
Balkin ER; Jia F; Miller WH; Lewis MR
Anticancer Res; 2011 Oct; 31(10):3143-9. PubMed ID: 21965720
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts.
Santini C; Kuil J; Bunschoten A; Pool S; de Blois E; Ridwan Y; Essers J; Bernsen MR; van Leeuwen FW; de Jong M
J Nucl Med; 2016 Aug; 57(8):1289-95. PubMed ID: 27127222
[TBL] [Abstract][Full Text] [Related]
12. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
13. MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids.
Sun X; Fang H; Li X; Rossin R; Welch MJ; Taylor JS
Bioconjug Chem; 2005; 16(2):294-305. PubMed ID: 15769082
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
15. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours.
Rao PS; Tian X; Qin W; Aruva MR; Sauter ER; Thakur ML; Wickstrom E
Nucl Med Commun; 2003 Aug; 24(8):857-63. PubMed ID: 12869817
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.
Zhou Z; Wagh NK; Ogbomo SM; Shi W; Jia Y; Brusnahan SK; Garrison JC
J Nucl Med; 2013 Sep; 54(9):1605-12. PubMed ID: 23896558
[TBL] [Abstract][Full Text] [Related]
18. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
19. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma.
Statham-Ringen KA; Selting KA; Lattimer JC; Henry CJ; Green JA; Bryan JN; Jia F; Lewis MR
Am J Vet Res; 2012 May; 73(5):681-8. PubMed ID: 22533400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]